AMENDMENTS TO THE CLAIMS

1. (Previously presented) A compound having the formula I:

$$Y \xrightarrow{X} \xrightarrow{R_1} \xrightarrow{R_2} \xrightarrow{N} \xrightarrow{N} \xrightarrow{N}$$

or a stereoisomer, tautomer, or pharmaceutically acceptable salt-thereof, wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heterocyclyl, and
- (3) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) $-N(R^{1x})$ -,
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -,
- (3) -O-,
- (4) -S-,
- (5) -SO-,
- (6) $-SO_{2}$ -,
- (7) $-C(R^{2x}, R^{3x})$ -, and

wherein R^{1x}, R^{2x}, and R^{3x} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted C_1 - C_6 -alkyl,
- (c) substituted or unsubstituted C₂-C₆-alkenyl,
- (d) substituted or unsubstituted C₂-C₆-alkynyl,
- (e) substituted or unsubstituted aryl,

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLIC} 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100

- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R₁ is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- (3) -COOH,
- (4) halo,
- (5) $-OR^{1t}$, and
- (6) $-NHR^{1t}$,

wherein R1t is H or C1-C6-alkyl;

R₂ is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and

W is selected from the group consisting of

(1) $-N(R^{1w}, R^{2w})$, and

(2)
$$R^{4w} \stackrel{|}{=} \sum_{Z}^{N} (CH_2)r,$$

wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) substituted or unsubstituted aryl,
- (b) substituted or unsubstituted heterocyclyl, and
- (c) substituted or unsubstituted heteroaryl,

Z is selected from the group consisting of

- (a) -O-,
- (b) -NR^z-,
- (c) -S-,
- (d) -SO-,
- (e) $-SO_2$ -, and

(f) $-CH_{2}$ -,

wherein R^z is H or substituted or unsubstituted alkyl group; and R^{4w} is selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted C₁-C₆-alkyl,
- (c) $-COOR^{5w}$,
- (d) $-\text{CONH}_2$,
- (e) $-OR^{5w}$, and
- (f) $-NHR^{5w}$,

wherein R^{5w} is H or C_1 - C_6 -alkyl; and r is 0, 1, or 2;

with the proviso that when R_2 is phenyl independently substituted with one to five substituents selected from hydrogen, cycloalkyl, heterocycloalkyl, halo, nitro, amino, sulphonamido, or alkylsulphonylamino, R_1 is hydrogen, haloalkyl, alkyl, or halo, and X is NR^{1x} , then Y is substituted or unsubstituted heterocyclyl.

2. (Previously presented) The compound of claim 1, wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heterocyclyl, and
- (3) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) $-N(R^{1x})-$,
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{--}C_6\text{--alkyl}$; and

W is selected from the group consisting of

$$R^{4w}$$

wherein Z is -O- or -NRz-, wherein R^{4w} is H or substituted or unsubstituted C_1 - C_6 -alkyl.

3. (Previously presented) The compound of claim 1, wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted heterocyclyl,
- (2) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) $-N(R^{1x})$ -,
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

$$(3) \qquad -N \qquad N-$$

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl}$; and

W is selected from the group consisting of

$$R^{4w}$$

wherein Z is -O- or -NRz-, wherein R^{4w} is H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl}.$

4. (Previously presented) The compound of claim 1, wherein

Y is substituted or unsubstituted aryl;

X is selected from the group consisting of

- (1) $-N(R^{1x})-,$
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS**LLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682 8100

$$(3) \qquad -N \qquad N-1$$

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl}$; and

W is selected from the group consisting of

$$R^{4w}$$

wherein Z is -O- or -NRz-, wherein R^{4w} is H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl}.$

- 5. (Previously presented) The compound of claim 1, whereinX is selected from the group consisting of
 - (1) $-N(R^{1x})$ -,
 - (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and
 - $(3) \qquad -N \qquad N-$

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl}$; and

W is selected from the group consisting of

$$R^{4w}$$

wherein Z is -O- or -NRz-, wherein R^{4w} is H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl}.$

6. (Previously presented) The compound of claim 1, wherein Y is selected from the group consisting of

- (1) substituted or unsubstituted heterocyclyl,
- (2) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) $-N(R^{1x})$ -,
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

$$(3) \qquad -N \qquad N-$$

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl};$

R₂ is substituted or unsubstituted aryl; and

W is
$$\stackrel{N}{Z}$$
, wherein Z is -O- or -NH-.

7. (Previously presented) The compound of claim 1, wherein

Y is substituted or unsubstituted aryl;

X is selected from the group consisting of

- (1) $-N(R^{1x})-$,
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl};$

 R_2 is substituted or unsubstituted aryl; and

W is
$$\stackrel{\mid}{Z}$$
, wherein Z is -O- or -NH-.

8. (Previously presented) The compound of claim 1, wherein

X is selected from the group consisting of

(1) $-N(R^{1x})-,$

(2)
$$-(CH_2)_m$$
- $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $C_1\text{-}C_6\text{-alkyl};$

R₂ is substituted or unsubstituted aryl; and

W is
$$\stackrel{|}{Z}$$
, wherein Z is -O- or -NH-.

9. (Previously presented) The compound of claim 1, having the formula II:

$$Y \xrightarrow{X} \xrightarrow{R_1} R_2$$

$$X \xrightarrow{N} N$$

wherein Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heterocyclyl, and
- (3) substituted or unsubstituted heteroaryl; and

X is selected from the group consisting of

- (1) $-N(R^{1x})-,$
- (2) $-(CH_2)_m$ - $C(R^{2x}, R^{3x})$ - $N(R^{1x})$ -, and

$$(3) \qquad -N \qquad N-$$

10. (Previously presented) The compound of claim 1, having the formula II:

$$Y \cdot X \xrightarrow{R_1} R_2$$
 $N \xrightarrow{N} N$
(II)

wherein Y and X, taken together, are selected from the group consisting of

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLIC 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100 11. (Original) The compound of claim 1, having the formula II:

wherein Y and X, taken together, are selected from the group consisting of

12. (Previously presented) A compound having the formula II:

$$Y \xrightarrow{X} \xrightarrow{R_1} \xrightarrow{R_2} \xrightarrow{R_3} \xrightarrow{R_4} \xrightarrow{R_4} \xrightarrow{R_4} \xrightarrow{R_5} \xrightarrow{R_5}$$

wherein, Y and X, taken together, are selected from the group consisting of

$$H_{3}C$$
 $H_{3}CO$
 $H_{3}CO$
 $H_{3}CO$
 $H_{3}CO$
 $H_{3}CO$
 $H_{3}CO$
 $H_{3}CO$
 $H_{4}CO$
 $H_{4}CO$
 $H_{5}CO$
 $H_{5}CO$
 $H_{7}CO$
 H_{7}

R₁ is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- (3) -COOH,
- (4) halo,
- (5) $-OR^{1t}$, and
- (6) -NHR^{1t},

wherein R^{1t} is H or C_1 - C_6 -alkyl; and

R₂ is selected from the group consisting of

- (1) substituted or unsubstituted aryl, and
- (2) substituted or unsubstituted heteroaryl.
- 13. (Previously presented) The compound of claim 1, having the formula III:

wherein R₃, R₄, R₅, R₆ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- (3) $-COORt^1$,
- (4) $-CONH_2$,

- (5) $-OR^{1t}$, and
- (6) $-NHR^{1t}$.
- 14. (Previously presented) The compound of claim 1, having the formula IV:

$$\begin{array}{c|cccc}
R_5 & R_6 & H & R_1 \\
N & N & N & N \\
N & R_3 & N & N
\end{array}$$
(IV)

wherein R₃, R₄, R₅, R₆ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- (3) -COOR^{1t},
- (4) -CONH₂
- (5) $-OR^{1t}$, and
- (6) -NHR^{1t}.
- 15. (Previously presented) The compound of claim 1, having the formula V:

wherein R₃, R₄, R₅, R₆ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLE 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100

- (3) -COOR^{1t},
- (4) -CONH₂
- (5) $-OR^{1t}$, and
- (6) -NHR 1t ; and

R^{2a} and R^{2b} are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) halo,
- (4) $-(CH_2)_q$ - $N(R^{2c}, R^{2d})$,
- (5) $-(CH_2)_q$ -N(R^{2c}, R^{2d})COR^{2e},
- (6) $-(CH_2)_q$ -OR^{2e},
- (7) $-(CH_2)_q$ -OCOR^{2e},
- (8) $-(CH_2)_q$ -OCOOR^{2e},
- (9) $-(CH_2)_q$ -COOR^{2e},
- (10) $-(CH_2)_q$ -CONR^{2c},
- (11) -CN,
- (12) $-NO_2$,
- (13) $-SO_2NH_2$,
- (14) -NHSO₂CH₃, and
- (15) $-SO_2R^{2f}$,

wherein R2c, R2d, R2e, and R2f are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted phenyl; and

q is 0, 1, 2, 3, or 4.

16. (Previously presented) A compound having the formula VI:

$$\begin{array}{c|c}
H \\
N \\
N \\
N \\
N
\end{array}$$

$$\begin{array}{c}
R_2 \\
N \\
N
\end{array}$$

$$\begin{array}{c}
(VI)
\end{array}$$

wherein R_2 is selected from the group consisting of

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLIC 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100 17. (Previously presented) The compound of claim 1, having the formula VII:

$$\begin{array}{c|cccc}
R_{10} & H & R_{1} \\
N & N & N \\
R_{9} & R_{7} & N & N
\end{array}$$
(VII)

wherein R₇, R₈, R₉, and R₁₀ are selected from the group consisting of

- (1) H.
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- $-COOR^{1t}$,
- (4) $-CONH_2$
- (5) $-OR^{1t}$, and
- (6) $-NHR^{1t}$.

18. (Original) The compound of claim 1, having the formula VIII:

$$\begin{array}{c|c}
R_{10} & H & R_{1} \\
N & N & R_{2} \\
R_{9} & R_{7} & N & N \\
R_{8} & N & N & N
\end{array}$$
(VIII)

wherein R₇, R₈, R₉, R₁₀ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) $-COOR^{1t}$,
- (4) $-\text{CONH}_2$,
- (5) $-OR^{1t}$, and

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSPILE
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (6) $-NHR^{1t}$.
- 19. (Previously presented) A compound having the formula IX:

$$\begin{array}{c|c}
H & & \\
N & & \\
R_7 & N & N
\end{array}$$
(IX)

wherein R^{1a} and R^{1b} are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) halo,
- (4) $-(CH_2)_q$ - $N(R^{2c}, R^{2d}),$
- (5) $-(CH_2)_q$ -N(R^{2c}, R^{2d})COR^{2e},
- (6) $-(CH_2)_q$ -OR^{2e},
- (7) $-(CH_2)_q$ -OCOR^{2e},
- (8) $-(CH_2)_q$ -OCOOR^{2e},
- (9) $-(CH_2)_q$ -COOR^{2e},
- (10) $-(CH_2)_q$ -CONR^{2c},
- (11) -CN,
- (12) $-NO_2$,
- (13) $-SO_2NH_2$,
- (14) -NHSO₂CH₃, and
- (15) $-SO_2R^{2f}$,

wherein R^{2c} , R^{2d} , R^{2e} , and R^{2f} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLUS} 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100

- $\begin{tabular}{ll} (c) & substituted or unsubstituted phenyl; and \\ wherein R_7 is selected from the group consisting of \\ \end{tabular}$
 - (1) H,
 - (2) substituted or unsubstituted C_1 - C_6 -alkyl,
 - (3) -COOR^{1t},
 - (4) $-CONH_2$,
 - (5) $-OR^{1t}$, and
 - (6) $-NHR^{1t}$.
- 20. (Previously presented) A compound having the formula X:

wherein R₂ is selected from the group consisting of

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100 21. (Previously presented) A compound having the formula XI:

wherein R^{2g} is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) -CONHR^{2h},
- (4) $-\text{CON}(R^{2h})$ - $(\text{CH}_2)_{2-3}$ - $N(R^{2h}, R^{2i})$,
- (5) $-COR^{2j}$,
- (6) $-CO_2R^{2j}$,
- (7) $-COC_1-C_6$ -alkyl- CO_2H ,
- (8) $-CH_2-OC(=O)R^{2i}$,
- (9) $-CH_2-OC(=O)NHCHR^{2i}CO_2R^{2j}$,

, and

(10) $-P(=O)(OR^{2k}, OR^{2p}),$ CO_2H

(11)

(12)

wherein R^{2h}, R²ⁱ, R^{2j}, R^{2k}, and R^{2p} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted aryl.
- 22. (Previously presented) A compound having the formula XII:

wherein R^{2g} is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) $-CONHR^{2h}$,
- (4) $-\text{CON}(R^{2h})$ - $(CH_2)_{2-3}$ - $N(R^{2h}, R^{2i})$,
- (5) $-COR^{2j}$,
- (6) $-CO_2R^{2j}$,
- (7) $-COC_1-C_6$ -alkyl- CO_2H ,
- (8) $-CH_2-OC(=O)R^{2i}$,
- (9) $-CH_2-OC(=O)NHCHR^{2i}CO_2R^{2j}$,
- (10) $-P(=O)(OR^{2k}, OR^{2p}),$ CO_2H OHOH
 , and

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS**110 1420 Fifth Avenue Suite 2800 Scattle, Washington 98101 206.682.8100

$$(12) \qquad \begin{matrix} 0 \\ N \\ S \\ O \end{matrix} ,$$

wherein R^{2h}, R²ⁱ, R^{2j}, R^{2k}, and R^{2p} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted aryl.
- 23. (Previously presented) A composition, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 24. (Previously presented) The composition of Claim 23 further comprising at least one additional agent for the treatment of breast cancer.
- 25. (Previously presented) The composition of Claim 24, wherein the at least one additional agent for the treatment of breast cancer is selected from irinotecan, topotecan, gemcitabine, imatinib mesylate, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.
- 26. (Previously presented) A method for treating breast cancer comprising administering to a subject in need of such treatment an effective amount of a compound of Claim 1.
- 27. (Original) The method of Claim 26, wherein the compound has an IC $_{50}$ value of less than about 20 μ M in a cell proliferation assay.

28-30. (Canceled)

31. (Previously presented) The method of Claim 26 further comprising administering to the human or animal subject at least one additional agent for the treatment of breast cancer.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSPILE
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206 682.8100

32. (Previously presented) The method of Claim 31, wherein the at least one additional agent for the treatment of breast cancer is selected from irinotecan, topotecan, gemcitabine, imatinib mesylate, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.

33-36. (Canceled)

- 37. (Previously presented) A compound of Claim 1, wherein R_2 is hydroxy-substituted phenyl.
- 38. (Previously presented) A compound of Claim 1, wherein R_2 is substituted or unsubstituted pyridinyl.
- 39. (Previously presented) A compound of Claim 1, wherein R₂ is substituted or unsubstituted pyrimidinyl.
 - 40. (Previously presented) A compound of Claim 1, wherein W is

$$R^{4w}$$
 $Z^{(CH_2)r}$.

- 41. (Previously presented) A compound of Claim 40, wherein R^{4w} is H, r is 1, and Z is O.
- 42. (Previously presented) A compound of Claim 1, wherein Y is substituted or unsubstituted heterocyclyl.
- 43. (Previously presented) A compound of Claim 1, wherein X is a O and Y is substituted or unsubstituted heterocyclyl.
 - 44. (Canceled)

- 45. (Previously presented) A compound of Claim 40, wherein R^{4w} is H, r is 1, Z is O, Y is substituted or unsubstituted heterocyclyl, R_1 is H, and R_2 is substituted or unsubstituted heteroaryl.
- 46. (Previously presented) A compound of Claim 40, wherein R^{4w} is H, r is 1, Z is O, X is O, Y is substituted or unsubstituted heterocyclyl, R_1 is H, and R_2 is substituted or unsubstituted heteroaryl.

47-53. (Canceled)

54. (Currently amended) A composition, comprising a compound having the formula:

$$Y \longrightarrow R_1$$
 R_2
 R_2
 R_2

wherein Y is substituted or unsubstituted heterocyclyl;

R₁ is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- (3) -COOH, <u>and</u>
- (4) halo[[,]]
- (5) -OR^{1t}, and
- (6) NHR^{1t};

wherein-R1t is H or C1-C6-alkyl;

R₂ is substituted aryl; and

W is substituted or unsubstituted morpholino;

at least one additional agent for the treatment of breast cancer, and a pharmaceutically acceptable carrier.

- 55. (Previously presented) The composition of Claim 54, wherein the at least one additional agent for the treatment of breast cancer is selected from irinotecan, topotecan, gemcitabine, imatinib mesylate, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.
- 56. (Currently amended) A method for treating breast cancer comprising administering to a subject in need of such treatment an effective amount of a compound having the formula:

$$R_1$$
 R_2
 R_2
 R_3

wherein Y is substituted or unsubstituted heterocyclyl;

 R_1 is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C_1 - C_6 -alkyl,
- (3) -COOH, <u>and</u>
- $(4) \quad halo[[,]]$
- (5) $-OR^{+t}$, and
- (6) NHR^{1†},

wherein R^{1t} is H or C₁-C₆-alkyl;

 R_2 is substituted aryl; and

W is substituted or unsubstituted morpholino.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPILE 1420 Fifth Avenue Suite 2800 Scattle, Washington 98101 206.682.8100

- 57. (Previously presented) The method of Claim 56 further comprising administering to the human or animal subject at least one additional agent for the treatment of breast cancer.
- 58. (Previously presented) The method of Claim 57, wherein the at least one additional agent for the treatment of breast cancer is selected from irinotecan, topotecan, gemeitabine, imatinib mesylate, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.